Anti-Aβ antibody target engagement: a response to Siemers et al.

about

Biometals and their therapeutic implications in Alzheimer's disease.mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures

P2860

Q38263669-C0F0E3D8-616A-4540-9CC0-394EC3FB7B97 Q41723015-29F6FECC-87BA-4C8C-B5A7-0B95CE5B4534

P2860

Anti-Aβ antibody target engagement: a response to Siemers et al.

Item

http://www.wikidata.org/entity/Q50628062

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Anti-Aβ antibody target engagement: a response to Siemers et al.

@en

Anti-Aβ antibody target engagement: a response to Siemers et al.

@nl

type

Item

label

Anti-Aβ antibody target engagement: a response to Siemers et al.

@en

Anti-Aβ antibody target engagement: a response to Siemers et al.

@nl

prefLabel

Anti-Aβ antibody target engagement: a response to Siemers et al.

@en

Anti-Aβ antibody target engagement: a response to Siemers et al.

@nl

P1476

Anti-Aβ antibody target engagement: a response to Siemers et al

@en

P2093

Adam Gunn

http://www.w3.org/2001/XMLSchema#string

Andrew D Watt

http://www.w3.org/2001/XMLSchema#string

Gabriela A N Crespi

http://www.w3.org/2001/XMLSchema#string

Kevin J Barnham

http://www.w3.org/2001/XMLSchema#string

Keyla A Perez

http://www.w3.org/2001/XMLSchema#string

Luke A Miles

http://www.w3.org/2001/XMLSchema#string

Michael W Parker

http://www.w3.org/2001/XMLSchema#string

Russell A Down

http://www.w3.org/2001/XMLSchema#string

Victor L Villemagne

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody multispecificity mediated by conformational diversity

Structures of Aβ-Related Peptide−Monoclonal Antibody Complexes ,

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab

Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease

ProteinChip array-based amyloid beta assays.

Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Small amphipathic molecules modulate secondary structure and amyloid fibril-forming kinetics of Alzheimer disease peptide Aβ(1-42).

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

P2888

s00401-014-1333-8

P304

611-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-014-1333-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

David B Ascher

C A McLean

P577

2014-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264798219

http://www.w3.org/2001/XMLSchema#string

P698

25120193

http://www.w3.org/2001/XMLSchema#string

Anti-Aβ antibody target engagement: a response to Siemers et al.

about

P2860

P2860

Anti-Aβ antibody target engagement: a response to Siemers et al.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698